List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Cancer is the second leading cause of death after heart disease in the US Chemotherapy is a mainstay of treatment after surgical removal of tumors but the balance of clinical benefit versus disabling or life threatening side effects is often uncertain Genotyping of cancers to identify mutated oncogenes has enabled an era of targeted therapy Drugs targeting ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIDDK

    DESCRIPTION provided by applicant Non alcoholic steatohepatitis NASH is characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosis and cirrhosis and high mortality rates NASH is frequently associated with other common metabolic abnormalities such as insulin resistance and visceral obesity Liver transplantation is curren ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Brain penetrant Hsp90 inhibitors for Alzheimer's disease

    SBC: YUMA THERAPEUTICS CORPORAITON            Topic: NIA

    DESCRIPTION provided by applicant Neurodegeneration in Alzheimerandapos s disease AD may result from deposition of A as plaques in brain tissue However less effort has been made to elucidate the role of tau containing neurofibrillary tangles NFTs in AD Accumulating evidence suggests that tau containing NFTs is an important component in the initiation and progression of AD and other neu ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Small Molecule Inhibitors of trans-Translation with Broad Spectrum Antibacterial

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Because of the emergence of resistance to known antibiotics there is a critical need for new antibacterial agents especially against Gram negative pathogens trans Translation is a biochemical pathway that is essential to many bacterial species including Neisseria gonorrhoeae Shigella flexneri and Mycoplasma spp A high throughput assay of trans translatio ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Inhibitors Targeting Early Steps of Human Cytomegalovirus Replication

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Human cytomegalovirus HCMV infection is a major cause of morbidity and mortality in immunosuppressed patients especially recipients of solid organ or bone marrow transplants HCMV infection of neonates is associated with deafness mental retardation and mortality Although five anti viral drugs GCV val GCV CDV PFA Foscarnet have been approved and lice ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Self-assembling density gradients for sickle cell diagnosis in low resource areas

    SBC: DAKTARI DIAGNOSTICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The World Health Organization has recently recognized sickle cell disease as a major global health concern The highest rates of sickle cell disease and sickle cell trait are seen in malaria endemic developing countries which also have the most severe resource constraints especially on clinical laboratory infrastructure Daktari Diagnostics a person vent ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Dendritic Cell-Targeted HIV Vaccine Product

    SBC: AVANT IMMUNOTHERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION This proposal is a unique collaboration between a small but full capability biotechnology company and a premier academic institution and laboratory to develop a novel product for clinical trials to prevent HIV infection This proposal describes a vaccine product aimed to provide a feasible and nontoxic way to elicit strong immunity in humans to HIV proteins and it will provide an ad ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. An intervention to improve adolescent headache self-management

    SBC: Inflexxion, Inc.            Topic: NICHD

    DESCRIPTION provided by applicant A mobile based intervention to improve adolescentsandapos headache self management Abstract Headache pain is a common and significant problem for adolescents King et al As headaches become more frequent and severe the negative impact on happiness increases and adolescents report less satisfaction with their health and with their life Sillampaa ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government